The Risk of Acute Kidney Injury and Its Impact on 30-Day and Long-Term Mortality after Transcatheter Aortic Valve Implantation

Table 1

Baseline data and periprocedural characteristics with respect to different access modes for valve replacement.

	Total	Transfemoral	Transapical	P
	𝑛=150	𝑛=96	𝑛=54
Women, 𝑛 (%)	91 (61)	66 (69)	25 (46)	0.006
Age, mean ± s.d., years	81 ± 7	82 ± 6	80 ± 7	0.2
Hypertension, 𝑛 (%)	115 (77)	69 (72)	46 (85)	<0.0001
Endstage renal failure, 𝑛 (%)	10 (7)	5 (5)	5 (9)	0.06
Hypercholesterolemia, 𝑛 (%)	51 (34)	31 (32)	20 (37)	0.27
Diabetes, 𝑛 (%)	42 (28)	25 (26)	17 (31)	0.56
Peripheral occlusive disease, 𝑛 (%)	37 (25)	10 (10)	27 (50)	<0.0001
Coronary heart disease, total, 𝑛 (%)	79 (53)	41 (43)	34 (63)	<0.05
(1) vessel disease	25 (17)	13 (14)	12 (22)
(2) vessel disease	20 (13)	14 (15)	6 (11)
(3) vessel disease	34 (23)	14 (15)	20 (37)
Previous myocardial infarction, 𝑛 (%)	36 (24)	22 (23)	14 (26)	0.42
Previous CABG, 𝑛 (%)	34 (23)	15 (16)	19 (35)	<0.0001
Previous stroke, 𝑛 (%)	14 (9)	7 (7)	7 (13)	0.024
Baseline creatinine, mean ± s.d., μmol/L	133.5 ± 109.6	116.7 ± 73.4	162.7 ± 150.3	0.013
GFR, mean ± s.d., mL/min/1,73 m^2	53 ± 22	55 ± 21	49 ± 22	0.11
Baseline hemoglobin, mean ± s.d., mmol/L	7.39 ± 1.06	7.39 ± 1.06	7.39 ± 0.99	0.8
Hemoglobin 24 hours after intervention, mean ± s.d., mmol/L	6.27 ± 0.81	6.27 ± 0.74	6.21 ± 0.93	0.53
Amount contrast dye, mean ± s.d., mL	147 ± 58	160 ± 57	125 ± 53	<0.0001
STS Score renal failure, %  ±s.d.	7.3 ± 4.2	6.8 ± 3.5	8.3 ± 5.1	0.054
STS Score mortality, %  ±s.d.	6.3 ± 3.5	5.7 ± 2.7	7.1 ± 4.5	0.024
EUROScore, %  ±s.d.	24 ± 14	22 ± 13	28 ± 16	0.02

All values are expressed as mean ± s.d. or 𝑛 (%).